Global Pruritus Drugs Market

Pruritus Drugs Comprehensive Study by Type (Antimicrobial, Cardiovascular,, Psychiatric/neurologic), Application (Cholestatic pruritus, Renal pruritus, Hematologic pruritus, Idiopathic generalized pruritus, Endocrine pruritus, Pruritus related to malignancy), Patient Type (Male, Fmale), Drug Administration (Topical, Oral, Parenteral), Skin Disease (Skin, Atopic Dermatitis, Allergic, Internal Diseases), Drug Class (Antihistamines, Corticosteroids), End Users (Hospital, Clinic, Others) Players and Region - Global Market Outlook to 2026

Pruritus Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Pruritus Drugs Market Scope?
Pruritus is a disease occurring in an itch and a need to scratch, potential causes involve medications or pregnancy. The most common cause of pruritus is Skin disease, pregnancy, dry skin, medications can also cause pruritus. Furthermore, on very rare occasions, pruritus can be due to cancer. Pruritus is considered chronic, if itching lasts six or more weeks. The pruritus drugs are prepared in semi-solid topical dosage forms, such as lotions, gels, and creams, which are easier to apply, are less painful and provides faster. This sign can occur in isolation or can be the result of another condition. The world health organization predicts that almost 900 million people in the world at any time suffer from skin diseases, and they are amongst the most common of all human health afflictions. The skin disorder is a powerful and cardinal symptom of atopic dermatitis or atopic eczema, whose prevalence in the Western countries is estimated around 23-44 million people in America are likely to suffer from chronic pruritus.

The Pruritus Drugs market study is being classified by Type (Antimicrobial, Cardiovascular, and psychiatric/neurologic), by Application (Cholestatic pruritus, Renal pruritus, Hematologic pruritus, Idiopathic generalized pruritus, Endocrine pruritus and Pruritus related to malignancy) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Pruritus Drugs market throughout the predicted period.

Allergan Plc (Ireland), Astellas Pharma Inc.( Japan), GlaxoSmithKline Plc (United Kingdom), Pfizer Inc. (United States), Intas Pharmaceuticals Ltd(India), Johnson & Johnson(United States), Sanofi (France), Eli Lilly and Company (United States) and Merck (United States) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Pruritus Drugs market by Type, Application and Region.

On the basis of geography, the market of Pruritus Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Influencing Market Trend
  • High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favourable research funding scenario,

Market Drivers
  • Drug development pressure on pharmaceuticals due to future patent expiries is one of the major driving factors of the growth
  • Prevalence of chronic pruritus in individuals across the globe

Opportunities
  • Growing prevalence of target diseases, unmet needs of pruritus patients pushing the drug development and creating growth opportunities for the market

Restraints
  • Non-medical therapies are suggested, Acupuncture, Light therapy

Challenges
  • The adverse effect of the drug used to treat the pruritus


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Pruritus Drugs Manufacturer, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Antimicrobial
  • Cardiovascular,
  • psychiatric/neurologic
By Application
  • Cholestatic pruritus
  • Renal pruritus
  • Hematologic pruritus
  • Idiopathic generalized pruritus
  • Endocrine pruritus
  • Pruritus related to malignancy
By Patient Type
  • Male
  • Fmale

By Drug Administration
  • Topical
  • Oral
  • Parenteral

By Skin Disease
  • Skin
  • Atopic Dermatitis
  • Allergic
  • Internal Diseases

By Drug Class
  • Antihistamines
  • Corticosteroids

By End Users
  • Hospital
  • Clinic
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Drug development pressure on pharmaceuticals due to future patent expiries is one of the major driving factors of the growth
      • 3.2.2. Prevalence of chronic pruritus in individuals across the globe
    • 3.3. Market Challenges
      • 3.3.1. The adverse effect of the drug used to treat the pruritus
    • 3.4. Market Trends
      • 3.4.1. High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favourable research funding scenario,
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pruritus Drugs, by Type, Application, Patient Type, Drug Administration, Skin Disease , Drug Class, End Users and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pruritus Drugs (Value)
      • 5.2.1. Global Pruritus Drugs by: Type (Value)
        • 5.2.1.1. Antimicrobial
        • 5.2.1.2. Cardiovascular,
        • 5.2.1.3. Psychiatric/neurologic
      • 5.2.2. Global Pruritus Drugs by: Application (Value)
        • 5.2.2.1. Cholestatic pruritus
        • 5.2.2.2. Renal pruritus
        • 5.2.2.3. Hematologic pruritus
        • 5.2.2.4. Idiopathic generalized pruritus
        • 5.2.2.5. Endocrine pruritus
        • 5.2.2.6. Pruritus related to malignancy
      • 5.2.3. Global Pruritus Drugs by: Patient Type (Value)
        • 5.2.3.1. Male
        • 5.2.3.2. Fmale
      • 5.2.4. Global Pruritus Drugs by: Drug Administration (Value)
        • 5.2.4.1. Topical
        • 5.2.4.2. Oral
        • 5.2.4.3. Parenteral
      • 5.2.5. Global Pruritus Drugs by: Drug Class (Value)
        • 5.2.5.1. Antihistamines
        • 5.2.5.2. Corticosteroids
      • 5.2.6. Global Pruritus Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Pruritus Drugs (Volume)
      • 5.3.1. Global Pruritus Drugs by: Type (Volume)
        • 5.3.1.1. Antimicrobial
        • 5.3.1.2. Cardiovascular,
        • 5.3.1.3. Psychiatric/neurologic
      • 5.3.2. Global Pruritus Drugs by: Application (Volume)
        • 5.3.2.1. Cholestatic pruritus
        • 5.3.2.2. Renal pruritus
        • 5.3.2.3. Hematologic pruritus
        • 5.3.2.4. Idiopathic generalized pruritus
        • 5.3.2.5. Endocrine pruritus
        • 5.3.2.6. Pruritus related to malignancy
      • 5.3.3. Global Pruritus Drugs by: Patient Type (Volume)
        • 5.3.3.1. Male
        • 5.3.3.2. Fmale
      • 5.3.4. Global Pruritus Drugs by: Drug Administration (Volume)
        • 5.3.4.1. Topical
        • 5.3.4.2. Oral
        • 5.3.4.3. Parenteral
      • 5.3.5. Global Pruritus Drugs by: Drug Class (Volume)
        • 5.3.5.1. Antihistamines
        • 5.3.5.2. Corticosteroids
      • 5.3.6. Global Pruritus Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Pruritus Drugs (Price)
      • 5.4.1. Global Pruritus Drugs by: Type (Price)
  • 6. Pruritus Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan Plc (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Astellas Pharma Inc.( Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Intas Pharmaceuticals Ltd(India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Pruritus Drugs Sale, by Type, Application, Patient Type, Drug Administration, Skin Disease , Drug Class, End Users and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pruritus Drugs (Value)
      • 7.2.1. Global Pruritus Drugs by: Type (Value)
        • 7.2.1.1. Antimicrobial
        • 7.2.1.2. Cardiovascular,
        • 7.2.1.3. Psychiatric/neurologic
      • 7.2.2. Global Pruritus Drugs by: Application (Value)
        • 7.2.2.1. Cholestatic pruritus
        • 7.2.2.2. Renal pruritus
        • 7.2.2.3. Hematologic pruritus
        • 7.2.2.4. Idiopathic generalized pruritus
        • 7.2.2.5. Endocrine pruritus
        • 7.2.2.6. Pruritus related to malignancy
      • 7.2.3. Global Pruritus Drugs by: Patient Type (Value)
        • 7.2.3.1. Male
        • 7.2.3.2. Fmale
      • 7.2.4. Global Pruritus Drugs by: Drug Administration (Value)
        • 7.2.4.1. Topical
        • 7.2.4.2. Oral
        • 7.2.4.3. Parenteral
      • 7.2.5. Global Pruritus Drugs by: Drug Class (Value)
        • 7.2.5.1. Antihistamines
        • 7.2.5.2. Corticosteroids
      • 7.2.6. Global Pruritus Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Pruritus Drugs (Volume)
      • 7.3.1. Global Pruritus Drugs by: Type (Volume)
        • 7.3.1.1. Antimicrobial
        • 7.3.1.2. Cardiovascular,
        • 7.3.1.3. Psychiatric/neurologic
      • 7.3.2. Global Pruritus Drugs by: Application (Volume)
        • 7.3.2.1. Cholestatic pruritus
        • 7.3.2.2. Renal pruritus
        • 7.3.2.3. Hematologic pruritus
        • 7.3.2.4. Idiopathic generalized pruritus
        • 7.3.2.5. Endocrine pruritus
        • 7.3.2.6. Pruritus related to malignancy
      • 7.3.3. Global Pruritus Drugs by: Patient Type (Volume)
        • 7.3.3.1. Male
        • 7.3.3.2. Fmale
      • 7.3.4. Global Pruritus Drugs by: Drug Administration (Volume)
        • 7.3.4.1. Topical
        • 7.3.4.2. Oral
        • 7.3.4.3. Parenteral
      • 7.3.5. Global Pruritus Drugs by: Drug Class (Volume)
        • 7.3.5.1. Antihistamines
        • 7.3.5.2. Corticosteroids
      • 7.3.6. Global Pruritus Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Pruritus Drugs (Price)
      • 7.4.1. Global Pruritus Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pruritus Drugs: by Type(USD Million)
  • Table 2. Pruritus Drugs Antimicrobial , by Region USD Million (2015-2020)
  • Table 3. Pruritus Drugs Cardiovascular, , by Region USD Million (2015-2020)
  • Table 4. Pruritus Drugs Psychiatric/neurologic , by Region USD Million (2015-2020)
  • Table 5. Pruritus Drugs: by Application(USD Million)
  • Table 6. Pruritus Drugs Cholestatic pruritus , by Region USD Million (2015-2020)
  • Table 7. Pruritus Drugs Renal pruritus , by Region USD Million (2015-2020)
  • Table 8. Pruritus Drugs Hematologic pruritus , by Region USD Million (2015-2020)
  • Table 9. Pruritus Drugs Idiopathic generalized pruritus , by Region USD Million (2015-2020)
  • Table 10. Pruritus Drugs Endocrine pruritus , by Region USD Million (2015-2020)
  • Table 11. Pruritus Drugs Pruritus related to malignancy , by Region USD Million (2015-2020)
  • Table 12. Pruritus Drugs: by Patient Type(USD Million)
  • Table 13. Pruritus Drugs Male , by Region USD Million (2015-2020)
  • Table 14. Pruritus Drugs Fmale , by Region USD Million (2015-2020)
  • Table 15. Pruritus Drugs: by Drug Administration(USD Million)
  • Table 16. Pruritus Drugs Topical , by Region USD Million (2015-2020)
  • Table 17. Pruritus Drugs Oral , by Region USD Million (2015-2020)
  • Table 18. Pruritus Drugs Parenteral , by Region USD Million (2015-2020)
  • Table 19. Pruritus Drugs: by Drug Class(USD Million)
  • Table 20. Pruritus Drugs Antihistamines , by Region USD Million (2015-2020)
  • Table 21. Pruritus Drugs Corticosteroids , by Region USD Million (2015-2020)
  • Table 22. South America Pruritus Drugs, by Country USD Million (2015-2020)
  • Table 23. South America Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 24. South America Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 25. South America Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 26. South America Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 27. South America Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 28. South America Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 29. South America Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 30. Brazil Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 31. Brazil Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 32. Brazil Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 33. Brazil Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 34. Brazil Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 35. Brazil Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 36. Brazil Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 37. Argentina Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 38. Argentina Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 39. Argentina Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 40. Argentina Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 41. Argentina Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 42. Argentina Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 43. Argentina Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 44. Rest of South America Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 45. Rest of South America Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 46. Rest of South America Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 47. Rest of South America Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 48. Rest of South America Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 49. Rest of South America Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 50. Rest of South America Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 51. Asia Pacific Pruritus Drugs, by Country USD Million (2015-2020)
  • Table 52. Asia Pacific Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 53. Asia Pacific Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 54. Asia Pacific Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 55. Asia Pacific Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 56. Asia Pacific Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 57. Asia Pacific Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 58. Asia Pacific Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 59. China Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 60. China Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 61. China Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 62. China Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 63. China Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 64. China Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 65. China Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 66. Japan Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 67. Japan Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 68. Japan Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 69. Japan Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 70. Japan Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 71. Japan Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 72. Japan Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 73. India Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 74. India Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 75. India Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 76. India Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 77. India Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 78. India Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 79. India Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 80. South Korea Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 81. South Korea Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 82. South Korea Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 83. South Korea Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 84. South Korea Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 85. South Korea Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 86. South Korea Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 87. Taiwan Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 88. Taiwan Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 89. Taiwan Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 90. Taiwan Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 91. Taiwan Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 92. Taiwan Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 93. Taiwan Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 94. Australia Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 95. Australia Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 96. Australia Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 97. Australia Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 98. Australia Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 99. Australia Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 100. Australia Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 101. Rest of Asia-Pacific Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 102. Rest of Asia-Pacific Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 103. Rest of Asia-Pacific Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 104. Rest of Asia-Pacific Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 105. Rest of Asia-Pacific Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 106. Rest of Asia-Pacific Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 107. Rest of Asia-Pacific Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 108. Europe Pruritus Drugs, by Country USD Million (2015-2020)
  • Table 109. Europe Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 110. Europe Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 111. Europe Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 112. Europe Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 113. Europe Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 114. Europe Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 115. Europe Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 116. Germany Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 117. Germany Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 118. Germany Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 119. Germany Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 120. Germany Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 121. Germany Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 122. Germany Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 123. France Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 124. France Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 125. France Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 126. France Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 127. France Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 128. France Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 129. France Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 130. Italy Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 131. Italy Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 132. Italy Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 133. Italy Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 134. Italy Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 135. Italy Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 136. Italy Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 137. United Kingdom Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 138. United Kingdom Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 139. United Kingdom Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 140. United Kingdom Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 141. United Kingdom Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 142. United Kingdom Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 143. United Kingdom Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 144. Netherlands Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 145. Netherlands Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 146. Netherlands Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 147. Netherlands Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 148. Netherlands Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 149. Netherlands Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 150. Netherlands Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 151. Rest of Europe Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 152. Rest of Europe Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 153. Rest of Europe Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 154. Rest of Europe Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 155. Rest of Europe Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 156. Rest of Europe Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 157. Rest of Europe Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 158. MEA Pruritus Drugs, by Country USD Million (2015-2020)
  • Table 159. MEA Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 160. MEA Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 161. MEA Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 162. MEA Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 163. MEA Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 164. MEA Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 165. MEA Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 166. Middle East Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 167. Middle East Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 168. Middle East Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 169. Middle East Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 170. Middle East Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 171. Middle East Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 172. Middle East Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 173. Africa Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 174. Africa Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 175. Africa Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 176. Africa Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 177. Africa Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 178. Africa Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 179. Africa Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 180. North America Pruritus Drugs, by Country USD Million (2015-2020)
  • Table 181. North America Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 182. North America Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 183. North America Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 184. North America Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 185. North America Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 186. North America Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 187. North America Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 188. United States Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 189. United States Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 190. United States Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 191. United States Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 192. United States Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 193. United States Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 194. United States Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 195. Canada Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 196. Canada Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 197. Canada Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 198. Canada Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 199. Canada Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 200. Canada Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 201. Canada Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 202. Mexico Pruritus Drugs, by Type USD Million (2015-2020)
  • Table 203. Mexico Pruritus Drugs, by Application USD Million (2015-2020)
  • Table 204. Mexico Pruritus Drugs, by Patient Type USD Million (2015-2020)
  • Table 205. Mexico Pruritus Drugs, by Drug Administration USD Million (2015-2020)
  • Table 206. Mexico Pruritus Drugs, by Skin Disease USD Million (2015-2020)
  • Table 207. Mexico Pruritus Drugs, by Drug Class USD Million (2015-2020)
  • Table 208. Mexico Pruritus Drugs, by End Users USD Million (2015-2020)
  • Table 209. Pruritus Drugs Sales: by Type(K Tons)
  • Table 210. Pruritus Drugs Sales Antimicrobial , by Region K Tons (2015-2020)
  • Table 211. Pruritus Drugs Sales Cardiovascular, , by Region K Tons (2015-2020)
  • Table 212. Pruritus Drugs Sales Psychiatric/neurologic , by Region K Tons (2015-2020)
  • Table 213. Pruritus Drugs Sales: by Application(K Tons)
  • Table 214. Pruritus Drugs Sales Cholestatic pruritus , by Region K Tons (2015-2020)
  • Table 215. Pruritus Drugs Sales Renal pruritus , by Region K Tons (2015-2020)
  • Table 216. Pruritus Drugs Sales Hematologic pruritus , by Region K Tons (2015-2020)
  • Table 217. Pruritus Drugs Sales Idiopathic generalized pruritus , by Region K Tons (2015-2020)
  • Table 218. Pruritus Drugs Sales Endocrine pruritus , by Region K Tons (2015-2020)
  • Table 219. Pruritus Drugs Sales Pruritus related to malignancy , by Region K Tons (2015-2020)
  • Table 220. Pruritus Drugs Sales: by Patient Type(K Tons)
  • Table 221. Pruritus Drugs Sales Male , by Region K Tons (2015-2020)
  • Table 222. Pruritus Drugs Sales Fmale , by Region K Tons (2015-2020)
  • Table 223. Pruritus Drugs Sales: by Drug Administration(K Tons)
  • Table 224. Pruritus Drugs Sales Topical , by Region K Tons (2015-2020)
  • Table 225. Pruritus Drugs Sales Oral , by Region K Tons (2015-2020)
  • Table 226. Pruritus Drugs Sales Parenteral , by Region K Tons (2015-2020)
  • Table 227. Pruritus Drugs Sales: by Drug Class(K Tons)
  • Table 228. Pruritus Drugs Sales Antihistamines , by Region K Tons (2015-2020)
  • Table 229. Pruritus Drugs Sales Corticosteroids , by Region K Tons (2015-2020)
  • Table 230. South America Pruritus Drugs Sales, by Country K Tons (2015-2020)
  • Table 231. South America Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 232. South America Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 233. South America Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 234. South America Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 235. South America Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 236. South America Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 237. South America Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 238. Brazil Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 239. Brazil Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 240. Brazil Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 241. Brazil Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 242. Brazil Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 243. Brazil Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 244. Brazil Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 245. Argentina Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 246. Argentina Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 247. Argentina Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 248. Argentina Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 249. Argentina Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 250. Argentina Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 251. Argentina Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 252. Rest of South America Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 253. Rest of South America Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 254. Rest of South America Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 255. Rest of South America Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 256. Rest of South America Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 257. Rest of South America Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 258. Rest of South America Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 259. Asia Pacific Pruritus Drugs Sales, by Country K Tons (2015-2020)
  • Table 260. Asia Pacific Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 261. Asia Pacific Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 262. Asia Pacific Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 263. Asia Pacific Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 264. Asia Pacific Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 265. Asia Pacific Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 266. Asia Pacific Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 267. China Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 268. China Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 269. China Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 270. China Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 271. China Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 272. China Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 273. China Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 274. Japan Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 275. Japan Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 276. Japan Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 277. Japan Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 278. Japan Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 279. Japan Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 280. Japan Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 281. India Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 282. India Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 283. India Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 284. India Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 285. India Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 286. India Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 287. India Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 288. South Korea Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 289. South Korea Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 290. South Korea Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 291. South Korea Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 292. South Korea Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 293. South Korea Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 294. South Korea Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 295. Taiwan Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 296. Taiwan Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 297. Taiwan Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 298. Taiwan Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 299. Taiwan Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 300. Taiwan Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 301. Taiwan Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 302. Australia Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 303. Australia Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 304. Australia Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 305. Australia Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 306. Australia Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 307. Australia Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 308. Australia Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 309. Rest of Asia-Pacific Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 310. Rest of Asia-Pacific Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 311. Rest of Asia-Pacific Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 312. Rest of Asia-Pacific Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 313. Rest of Asia-Pacific Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 314. Rest of Asia-Pacific Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 315. Rest of Asia-Pacific Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 316. Europe Pruritus Drugs Sales, by Country K Tons (2015-2020)
  • Table 317. Europe Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 318. Europe Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 319. Europe Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 320. Europe Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 321. Europe Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 322. Europe Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 323. Europe Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 324. Germany Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 325. Germany Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 326. Germany Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 327. Germany Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 328. Germany Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 329. Germany Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 330. Germany Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 331. France Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 332. France Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 333. France Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 334. France Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 335. France Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 336. France Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 337. France Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 338. Italy Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 339. Italy Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 340. Italy Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 341. Italy Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 342. Italy Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 343. Italy Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 344. Italy Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 345. United Kingdom Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 346. United Kingdom Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 347. United Kingdom Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 348. United Kingdom Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 349. United Kingdom Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 350. United Kingdom Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 351. United Kingdom Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 352. Netherlands Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 353. Netherlands Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 354. Netherlands Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 355. Netherlands Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 356. Netherlands Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 357. Netherlands Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 358. Netherlands Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 359. Rest of Europe Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 360. Rest of Europe Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 361. Rest of Europe Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 362. Rest of Europe Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 363. Rest of Europe Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 364. Rest of Europe Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 365. Rest of Europe Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 366. MEA Pruritus Drugs Sales, by Country K Tons (2015-2020)
  • Table 367. MEA Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 368. MEA Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 369. MEA Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 370. MEA Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 371. MEA Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 372. MEA Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 373. MEA Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 374. Middle East Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 375. Middle East Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 376. Middle East Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 377. Middle East Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 378. Middle East Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 379. Middle East Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 380. Middle East Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 381. Africa Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 382. Africa Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 383. Africa Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 384. Africa Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 385. Africa Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 386. Africa Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 387. Africa Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 388. North America Pruritus Drugs Sales, by Country K Tons (2015-2020)
  • Table 389. North America Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 390. North America Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 391. North America Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 392. North America Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 393. North America Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 394. North America Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 395. North America Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 396. United States Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 397. United States Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 398. United States Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 399. United States Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 400. United States Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 401. United States Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 402. United States Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 403. Canada Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 404. Canada Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 405. Canada Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 406. Canada Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 407. Canada Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 408. Canada Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 409. Canada Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 410. Mexico Pruritus Drugs Sales, by Type K Tons (2015-2020)
  • Table 411. Mexico Pruritus Drugs Sales, by Application K Tons (2015-2020)
  • Table 412. Mexico Pruritus Drugs Sales, by Patient Type K Tons (2015-2020)
  • Table 413. Mexico Pruritus Drugs Sales, by Drug Administration K Tons (2015-2020)
  • Table 414. Mexico Pruritus Drugs Sales, by Skin Disease K Tons (2015-2020)
  • Table 415. Mexico Pruritus Drugs Sales, by Drug Class K Tons (2015-2020)
  • Table 416. Mexico Pruritus Drugs Sales, by End Users K Tons (2015-2020)
  • Table 417. Pruritus Drugs: by Type(USD/Units)
  • Table 418. Company Basic Information, Sales Area and Its Competitors
  • Table 419. Company Basic Information, Sales Area and Its Competitors
  • Table 420. Company Basic Information, Sales Area and Its Competitors
  • Table 421. Company Basic Information, Sales Area and Its Competitors
  • Table 422. Company Basic Information, Sales Area and Its Competitors
  • Table 423. Company Basic Information, Sales Area and Its Competitors
  • Table 424. Company Basic Information, Sales Area and Its Competitors
  • Table 425. Company Basic Information, Sales Area and Its Competitors
  • Table 426. Company Basic Information, Sales Area and Its Competitors
  • Table 427. Pruritus Drugs: by Type(USD Million)
  • Table 428. Pruritus Drugs Antimicrobial , by Region USD Million (2021-2026)
  • Table 429. Pruritus Drugs Cardiovascular, , by Region USD Million (2021-2026)
  • Table 430. Pruritus Drugs Psychiatric/neurologic , by Region USD Million (2021-2026)
  • Table 431. Pruritus Drugs: by Application(USD Million)
  • Table 432. Pruritus Drugs Cholestatic pruritus , by Region USD Million (2021-2026)
  • Table 433. Pruritus Drugs Renal pruritus , by Region USD Million (2021-2026)
  • Table 434. Pruritus Drugs Hematologic pruritus , by Region USD Million (2021-2026)
  • Table 435. Pruritus Drugs Idiopathic generalized pruritus , by Region USD Million (2021-2026)
  • Table 436. Pruritus Drugs Endocrine pruritus , by Region USD Million (2021-2026)
  • Table 437. Pruritus Drugs Pruritus related to malignancy , by Region USD Million (2021-2026)
  • Table 438. Pruritus Drugs: by Patient Type(USD Million)
  • Table 439. Pruritus Drugs Male , by Region USD Million (2021-2026)
  • Table 440. Pruritus Drugs Fmale , by Region USD Million (2021-2026)
  • Table 441. Pruritus Drugs: by Drug Administration(USD Million)
  • Table 442. Pruritus Drugs Topical , by Region USD Million (2021-2026)
  • Table 443. Pruritus Drugs Oral , by Region USD Million (2021-2026)
  • Table 444. Pruritus Drugs Parenteral , by Region USD Million (2021-2026)
  • Table 445. Pruritus Drugs: by Drug Class(USD Million)
  • Table 446. Pruritus Drugs Antihistamines , by Region USD Million (2021-2026)
  • Table 447. Pruritus Drugs Corticosteroids , by Region USD Million (2021-2026)
  • Table 448. South America Pruritus Drugs, by Country USD Million (2021-2026)
  • Table 449. South America Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 450. South America Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 451. South America Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 452. South America Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 453. South America Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 454. South America Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 455. South America Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 456. Brazil Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 457. Brazil Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 458. Brazil Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 459. Brazil Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 460. Brazil Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 461. Brazil Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 462. Brazil Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 463. Argentina Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 464. Argentina Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 465. Argentina Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 466. Argentina Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 467. Argentina Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 468. Argentina Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 469. Argentina Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 470. Rest of South America Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 471. Rest of South America Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 472. Rest of South America Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 473. Rest of South America Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 474. Rest of South America Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 475. Rest of South America Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 476. Rest of South America Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 477. Asia Pacific Pruritus Drugs, by Country USD Million (2021-2026)
  • Table 478. Asia Pacific Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 479. Asia Pacific Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 480. Asia Pacific Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 481. Asia Pacific Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 482. Asia Pacific Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 483. Asia Pacific Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 484. Asia Pacific Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 485. China Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 486. China Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 487. China Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 488. China Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 489. China Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 490. China Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 491. China Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 492. Japan Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 493. Japan Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 494. Japan Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 495. Japan Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 496. Japan Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 497. Japan Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 498. Japan Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 499. India Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 500. India Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 501. India Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 502. India Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 503. India Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 504. India Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 505. India Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 506. South Korea Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 507. South Korea Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 508. South Korea Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 509. South Korea Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 510. South Korea Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 511. South Korea Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 512. South Korea Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 513. Taiwan Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 514. Taiwan Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 515. Taiwan Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 516. Taiwan Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 517. Taiwan Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 518. Taiwan Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 519. Taiwan Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 520. Australia Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 521. Australia Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 522. Australia Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 523. Australia Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 524. Australia Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 525. Australia Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 526. Australia Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 527. Rest of Asia-Pacific Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 528. Rest of Asia-Pacific Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 529. Rest of Asia-Pacific Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 530. Rest of Asia-Pacific Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 531. Rest of Asia-Pacific Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 532. Rest of Asia-Pacific Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 533. Rest of Asia-Pacific Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 534. Europe Pruritus Drugs, by Country USD Million (2021-2026)
  • Table 535. Europe Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 536. Europe Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 537. Europe Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 538. Europe Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 539. Europe Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 540. Europe Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 541. Europe Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 542. Germany Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 543. Germany Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 544. Germany Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 545. Germany Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 546. Germany Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 547. Germany Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 548. Germany Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 549. France Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 550. France Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 551. France Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 552. France Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 553. France Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 554. France Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 555. France Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 556. Italy Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 557. Italy Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 558. Italy Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 559. Italy Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 560. Italy Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 561. Italy Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 562. Italy Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 563. United Kingdom Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 564. United Kingdom Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 565. United Kingdom Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 566. United Kingdom Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 567. United Kingdom Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 568. United Kingdom Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 569. United Kingdom Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 570. Netherlands Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 571. Netherlands Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 572. Netherlands Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 573. Netherlands Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 574. Netherlands Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 575. Netherlands Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 576. Netherlands Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 577. Rest of Europe Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 578. Rest of Europe Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 579. Rest of Europe Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 580. Rest of Europe Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 581. Rest of Europe Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 582. Rest of Europe Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 583. Rest of Europe Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 584. MEA Pruritus Drugs, by Country USD Million (2021-2026)
  • Table 585. MEA Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 586. MEA Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 587. MEA Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 588. MEA Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 589. MEA Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 590. MEA Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 591. MEA Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 592. Middle East Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 593. Middle East Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 594. Middle East Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 595. Middle East Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 596. Middle East Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 597. Middle East Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 598. Middle East Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 599. Africa Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 600. Africa Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 601. Africa Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 602. Africa Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 603. Africa Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 604. Africa Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 605. Africa Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 606. North America Pruritus Drugs, by Country USD Million (2021-2026)
  • Table 607. North America Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 608. North America Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 609. North America Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 610. North America Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 611. North America Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 612. North America Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 613. North America Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 614. United States Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 615. United States Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 616. United States Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 617. United States Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 618. United States Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 619. United States Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 620. United States Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 621. Canada Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 622. Canada Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 623. Canada Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 624. Canada Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 625. Canada Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 626. Canada Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 627. Canada Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 628. Mexico Pruritus Drugs, by Type USD Million (2021-2026)
  • Table 629. Mexico Pruritus Drugs, by Application USD Million (2021-2026)
  • Table 630. Mexico Pruritus Drugs, by Patient Type USD Million (2021-2026)
  • Table 631. Mexico Pruritus Drugs, by Drug Administration USD Million (2021-2026)
  • Table 632. Mexico Pruritus Drugs, by Skin Disease USD Million (2021-2026)
  • Table 633. Mexico Pruritus Drugs, by Drug Class USD Million (2021-2026)
  • Table 634. Mexico Pruritus Drugs, by End Users USD Million (2021-2026)
  • Table 635. Pruritus Drugs Sales: by Type(K Tons)
  • Table 636. Pruritus Drugs Sales Antimicrobial , by Region K Tons (2021-2026)
  • Table 637. Pruritus Drugs Sales Cardiovascular, , by Region K Tons (2021-2026)
  • Table 638. Pruritus Drugs Sales Psychiatric/neurologic , by Region K Tons (2021-2026)
  • Table 639. Pruritus Drugs Sales: by Application(K Tons)
  • Table 640. Pruritus Drugs Sales Cholestatic pruritus , by Region K Tons (2021-2026)
  • Table 641. Pruritus Drugs Sales Renal pruritus , by Region K Tons (2021-2026)
  • Table 642. Pruritus Drugs Sales Hematologic pruritus , by Region K Tons (2021-2026)
  • Table 643. Pruritus Drugs Sales Idiopathic generalized pruritus , by Region K Tons (2021-2026)
  • Table 644. Pruritus Drugs Sales Endocrine pruritus , by Region K Tons (2021-2026)
  • Table 645. Pruritus Drugs Sales Pruritus related to malignancy , by Region K Tons (2021-2026)
  • Table 646. Pruritus Drugs Sales: by Patient Type(K Tons)
  • Table 647. Pruritus Drugs Sales Male , by Region K Tons (2021-2026)
  • Table 648. Pruritus Drugs Sales Fmale , by Region K Tons (2021-2026)
  • Table 649. Pruritus Drugs Sales: by Drug Administration(K Tons)
  • Table 650. Pruritus Drugs Sales Topical , by Region K Tons (2021-2026)
  • Table 651. Pruritus Drugs Sales Oral , by Region K Tons (2021-2026)
  • Table 652. Pruritus Drugs Sales Parenteral , by Region K Tons (2021-2026)
  • Table 653. Pruritus Drugs Sales: by Drug Class(K Tons)
  • Table 654. Pruritus Drugs Sales Antihistamines , by Region K Tons (2021-2026)
  • Table 655. Pruritus Drugs Sales Corticosteroids , by Region K Tons (2021-2026)
  • Table 656. South America Pruritus Drugs Sales, by Country K Tons (2021-2026)
  • Table 657. South America Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 658. South America Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 659. South America Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 660. South America Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 661. South America Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 662. South America Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 663. South America Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 664. Brazil Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 665. Brazil Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 666. Brazil Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 667. Brazil Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 668. Brazil Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 669. Brazil Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 670. Brazil Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 671. Argentina Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 672. Argentina Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 673. Argentina Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 674. Argentina Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 675. Argentina Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 676. Argentina Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 677. Argentina Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 678. Rest of South America Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 679. Rest of South America Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 680. Rest of South America Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 681. Rest of South America Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 682. Rest of South America Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 683. Rest of South America Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 684. Rest of South America Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 685. Asia Pacific Pruritus Drugs Sales, by Country K Tons (2021-2026)
  • Table 686. Asia Pacific Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 687. Asia Pacific Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 688. Asia Pacific Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 689. Asia Pacific Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 690. Asia Pacific Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 691. Asia Pacific Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 692. Asia Pacific Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 693. China Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 694. China Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 695. China Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 696. China Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 697. China Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 698. China Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 699. China Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 700. Japan Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 701. Japan Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 702. Japan Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 703. Japan Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 704. Japan Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 705. Japan Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 706. Japan Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 707. India Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 708. India Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 709. India Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 710. India Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 711. India Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 712. India Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 713. India Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 714. South Korea Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 715. South Korea Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 716. South Korea Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 717. South Korea Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 718. South Korea Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 719. South Korea Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 720. South Korea Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 721. Taiwan Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 722. Taiwan Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 723. Taiwan Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 724. Taiwan Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 725. Taiwan Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 726. Taiwan Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 727. Taiwan Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 728. Australia Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 729. Australia Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 730. Australia Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 731. Australia Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 732. Australia Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 733. Australia Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 734. Australia Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 735. Rest of Asia-Pacific Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 736. Rest of Asia-Pacific Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 737. Rest of Asia-Pacific Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 738. Rest of Asia-Pacific Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 739. Rest of Asia-Pacific Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 740. Rest of Asia-Pacific Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 741. Rest of Asia-Pacific Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 742. Europe Pruritus Drugs Sales, by Country K Tons (2021-2026)
  • Table 743. Europe Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 744. Europe Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 745. Europe Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 746. Europe Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 747. Europe Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 748. Europe Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 749. Europe Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 750. Germany Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 751. Germany Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 752. Germany Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 753. Germany Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 754. Germany Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 755. Germany Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 756. Germany Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 757. France Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 758. France Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 759. France Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 760. France Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 761. France Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 762. France Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 763. France Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 764. Italy Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 765. Italy Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 766. Italy Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 767. Italy Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 768. Italy Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 769. Italy Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
  • Table 770. Italy Pruritus Drugs Sales, by End Users K Tons (2021-2026)
  • Table 771. United Kingdom Pruritus Drugs Sales, by Type K Tons (2021-2026)
  • Table 772. United Kingdom Pruritus Drugs Sales, by Application K Tons (2021-2026)
  • Table 773. United Kingdom Pruritus Drugs Sales, by Patient Type K Tons (2021-2026)
  • Table 774. United Kingdom Pruritus Drugs Sales, by Drug Administration K Tons (2021-2026)
  • Table 775. United Kingdom Pruritus Drugs Sales, by Skin Disease K Tons (2021-2026)
  • Table 776. United Kingdom Pruritus Drugs Sales, by Drug Class K Tons (2021-2026)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pruritus Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Pruritus Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Pruritus Drugs: by Patient Type USD Million (2015-2020)
  • Figure 7. Global Pruritus Drugs: by Drug Administration USD Million (2015-2020)
  • Figure 8. Global Pruritus Drugs: by Drug Class USD Million (2015-2020)
  • Figure 9. South America Pruritus Drugs Share (%), by Country
  • Figure 10. Asia Pacific Pruritus Drugs Share (%), by Country
  • Figure 11. Europe Pruritus Drugs Share (%), by Country
  • Figure 12. MEA Pruritus Drugs Share (%), by Country
  • Figure 13. North America Pruritus Drugs Share (%), by Country
  • Figure 14. Global Pruritus Drugs: by Type K Tons (2015-2020)
  • Figure 15. Global Pruritus Drugs: by Application K Tons (2015-2020)
  • Figure 16. Global Pruritus Drugs: by Patient Type K Tons (2015-2020)
  • Figure 17. Global Pruritus Drugs: by Drug Administration K Tons (2015-2020)
  • Figure 18. Global Pruritus Drugs: by Drug Class K Tons (2015-2020)
  • Figure 19. South America Pruritus Drugs Share (%), by Country
  • Figure 20. Asia Pacific Pruritus Drugs Share (%), by Country
  • Figure 21. Europe Pruritus Drugs Share (%), by Country
  • Figure 22. MEA Pruritus Drugs Share (%), by Country
  • Figure 23. North America Pruritus Drugs Share (%), by Country
  • Figure 24. Global Pruritus Drugs: by Type USD/Units (2015-2020)
  • Figure 25. Global Pruritus Drugs share by Players 2020 (%)
  • Figure 26. Global Pruritus Drugs share by Players (Top 3) 2020(%)
  • Figure 27. Global Pruritus Drugs share by Players (Top 5) 2020(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Allergan Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Allergan Plc (Ireland) Revenue: by Geography 2020
  • Figure 31. Astellas Pharma Inc.( Japan) Revenue, Net Income and Gross profit
  • Figure 32. Astellas Pharma Inc.( Japan) Revenue: by Geography 2020
  • Figure 33. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 35. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Intas Pharmaceuticals Ltd(India) Revenue, Net Income and Gross profit
  • Figure 38. Intas Pharmaceuticals Ltd(India) Revenue: by Geography 2020
  • Figure 39. Johnson & Johnson(United States) Revenue, Net Income and Gross profit
  • Figure 40. Johnson & Johnson(United States) Revenue: by Geography 2020
  • Figure 41. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 42. Sanofi (France) Revenue: by Geography 2020
  • Figure 43. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 44. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 45. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 46. Merck (United States) Revenue: by Geography 2020
  • Figure 47. Global Pruritus Drugs: by Type USD Million (2021-2026)
  • Figure 48. Global Pruritus Drugs: by Application USD Million (2021-2026)
  • Figure 49. Global Pruritus Drugs: by Patient Type USD Million (2021-2026)
  • Figure 50. Global Pruritus Drugs: by Drug Administration USD Million (2021-2026)
  • Figure 51. Global Pruritus Drugs: by Drug Class USD Million (2021-2026)
  • Figure 52. South America Pruritus Drugs Share (%), by Country
  • Figure 53. Asia Pacific Pruritus Drugs Share (%), by Country
  • Figure 54. Europe Pruritus Drugs Share (%), by Country
  • Figure 55. MEA Pruritus Drugs Share (%), by Country
  • Figure 56. North America Pruritus Drugs Share (%), by Country
  • Figure 57. Global Pruritus Drugs: by Type K Tons (2021-2026)
  • Figure 58. Global Pruritus Drugs: by Application K Tons (2021-2026)
  • Figure 59. Global Pruritus Drugs: by Patient Type K Tons (2021-2026)
  • Figure 60. Global Pruritus Drugs: by Drug Administration K Tons (2021-2026)
  • Figure 61. Global Pruritus Drugs: by Drug Class K Tons (2021-2026)
  • Figure 62. South America Pruritus Drugs Share (%), by Country
  • Figure 63. Asia Pacific Pruritus Drugs Share (%), by Country
  • Figure 64. Europe Pruritus Drugs Share (%), by Country
  • Figure 65. MEA Pruritus Drugs Share (%), by Country
  • Figure 66. North America Pruritus Drugs Share (%), by Country
  • Figure 67. Global Pruritus Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Allergan Plc (Ireland)
  • Astellas Pharma Inc.( Japan)
  • GlaxoSmithKline Plc (United Kingdom)
  • Pfizer Inc. (United States)
  • Intas Pharmaceuticals Ltd(India)
  • Johnson & Johnson(United States)
  • Sanofi (France)
  • Eli Lilly and Company (United States)
  • Merck (United States)
Select User Access Type

Key Highlights of Report


Mar 2021 209 Pages 86 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pruritus Drugs Market Quantitative research analysis
Global Pruritus Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Pruritus Drugs market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Pruritus Drugs market are Allergan Plc (Ireland), Astellas Pharma Inc.( Japan), GlaxoSmithKline Plc (United Kingdom), Pfizer Inc. (United States), Intas Pharmaceuticals Ltd(India), Johnson & Johnson(United States), Sanofi (France), Eli Lilly and Company (United States) and Merck (United States), to name a few.
In this highly competitive & fast evolving Pruritus Drugs industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Pruritus Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Solid Tumor Drugs Comprehensive Study by Type (Small Molecules, Biologics), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others), Drug (Entrectinib, K...
$ 3750
Reishi Mushroom Supplements Comprehensive Study by End User Industries (Food & Beverage, Healthcare, Personal Care), Form (Liquid Extract, Powder Extract), Product (Organic Reishi Mushroom Extract, C...
$ 3450
Anti Ageing Ingredients Comprehensive Study by Type (Chemical Peels, Sunscreen Ingredients, Peptides, Hyaluronic Acid, Anti-Oxidants, Retinol, Niacinamide, Others), Application (Cosmetics, Food & Bev...
$ 3350
Heparin Injection Comprehensive Study by Type (1,000 USP/mL, 5,000 USP/mL, 10,000 USP/mL, 20,000 USP/mL), Application (Thrombosis,, Pulmonary Embolism, Hemodialysis, Others), Heparin Type (Unfraction...
$ 3650
Opioid Use Disorder Comprehensive Study by Application (Moderate Pain Treatment, Severe Pain Treatment), Drug (Buprenorphine (Bunavail) Players and Region - Global Market Outlook to 2026
$ 3500
Esophageal Cancer Drugs Comprehensive Study by Type (Carboplatin, Oxaliplatin, Cisplatin, Paclitaxel), Application (Hospitals, Cancer Clinics), End- User (Men, Women) Players and Region - Global Mark...
$ 3500